Semaglutide
Semaglutide is a GLP-1 receptor agonist used — depending on the brand and form — for weight management, cardiovascular risk reduction, type 2 diabetes blood sugar control, and liver disease treatment.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 6 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
Semaglutide (Wegovy) carries a serious warning about a potential risk of thyroid tumors. In animal studies, semaglutide caused thyroid tumors — including a type called medullary thyroid carcinoma (MTC) — in rodents. Whether this happens in humans is not yet known. Because of this uncertainty, Wegovy must not be used by anyone with a personal or family history of medullary thyroid cancer or a related genetic condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). If you are using Wegovy, watch for warning signs of thyroid problems: a lump or mass in the neck, difficulty swallowing, shortness of breath, or a hoarse voice that doesn't go away. Tell your doctor immediately if you notice any of these symptoms.
📖 Semaglutide: Patient Information Guide
A plain-language walkthrough of Semaglutide — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Semaglutide is approved for several different conditions across its branded products — always check which brand and form your prescription is for.
- Wegovy injection (once weekly, subcutaneous): weight reduction in adults with obesity or in adults with overweight who have at least one weight-related health condition; weight reduction in children aged 12 and older with obesity; reducing the risk of heart attack, stroke, or cardiovascular death in adults with established heart disease and obesity or overweight; treatment of MASH (a serious liver condition with moderate-to-advanced scarring) in adults — this last use is under accelerated approval
- Wegovy tablets (once daily, oral): weight reduction in adults with obesity or in adults with overweight with at least one weight-related health condition; reducing the risk of heart attack, stroke, or cardiovascular death in adults with established heart disease and obesity or overweight
- Ozempic injection (once weekly, subcutaneous): improving blood sugar control in adults with type 2 diabetes; reducing the risk of heart attack, stroke, or cardiovascular death in adults with type 2 diabetes and established heart disease
- All forms are used alongside a reduced-calorie diet and increased physical activity
- Ozempic is not approved for type 1 diabetes; Wegovy tablets are not approved for MASH or for use in children
⚙️How it works▾
Semaglutide is a close copy of GLP-1, a natural hormone your gut releases after you eat. It locks onto GLP-1 receptors in the pancreas — triggering insulin release when blood sugar is high and dialing back glucagon (a hormone that raises blood sugar) — and in the brain, where it reduces appetite and calorie intake. It also slows stomach emptying, which means sugar from meals enters the bloodstream more gradually. Together, these effects lower blood sugar, reduce hunger, and support weight loss.
For heart protection, the exact mechanism isn't fully understood. For the liver condition MASH, the benefit likely involves weight loss and other pathways, though the full picture hasn't been worked out yet.
💊How it's taken▾
How you take semaglutide depends entirely on which product you have been prescribed — do not switch products without guidance from your prescriber.
- Wegovy injection: Once-weekly injection under the skin of the abdomen, thigh, or upper arm, on the same day each week, at any time of day, with or without food. The dose starts low and is gradually increased over several months.
- Wegovy tablet: Once daily by mouth, on an empty stomach every morning, with up to 4 ounces of water only. Swallow whole — do not crush or chew. Wait at least 30 minutes before eating, drinking, or taking other oral medications. Dose is also gradually increased.
- Ozempic injection: Once-weekly injection under the skin of the abdomen, thigh, or upper arm, at any time of day, with or without food. If you miss a dose, take it within 5 days; if more than 5 days have passed, skip it and resume your normal schedule. Never share your pen with another person.
🤒Side effects — in detail▾
Stomach-related side effects are the most common, especially when starting or increasing the dose.
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Stomach pain or cramping
- Headache
- Fatigue
- Heartburn or acid reflux
- Dizziness
- Bloating or burping
- Hair loss
These effects are usually most noticeable early in treatment and tend to improve over time. However, if you experience severe, persistent stomach pain, signs of low blood sugar, signs of kidney problems, or any symptoms of a serious allergic reaction, seek medical attention right away.
⚠️Warnings & precautions▾
- Thyroid tumor risk: Animal studies showed thyroid tumors with semaglutide. The human risk is unknown. Do not use if you or a family member has had medullary thyroid cancer or MEN 2. Watch for a neck lump, trouble swallowing, shortness of breath, or persistent hoarseness.
- Pancreatitis: Serious, sometimes life-threatening pancreas inflammation has been reported. Seek immediate care for severe stomach pain that may radiate to the back.
- Low blood sugar (hypoglycemia): Risk increases if you also take insulin or sulfonylurea diabetes pills. Your doctor may adjust those doses. Know the signs: shakiness, sweating, confusion, rapid heartbeat.
- Kidney injury: Severe vomiting or diarrhea can cause dehydration and lead to acute kidney injury. Stay hydrated and report severe GI symptoms to your doctor promptly.
- Gallbladder disease: Gallstones and gallbladder inflammation have been reported. Tell your doctor about any upper-right belly pain.
- Diabetic eye disease (retinopathy): Ozempic was associated with worsening of diabetic eye complications in clinical trials, particularly in people with a prior history of retinopathy. Monitor closely with your eye doctor.
- Serious allergic reactions: Anaphylaxis and severe swelling (angioedema) have been reported. Stop use and get emergency help immediately if this occurs.
- Surgery and anesthesia: Because semaglutide slows stomach emptying, there is a risk of inhaling stomach contents during general anesthesia. Always tell your surgical team you are on this medication before any procedure.
🔀What it interacts with▾
Semaglutide has a few important interactions to be aware of — tell your doctor and pharmacist about all medications, vitamins, and supplements you take.
- Insulin or sulfonylureas (e.g., glipizide, glimepiride): combining these with semaglutide raises the risk of dangerously low blood sugar; your doctor may reduce those doses when starting semaglutide
- Other oral medications: because semaglutide slows stomach emptying, it could affect how quickly pills are absorbed; use caution and flag any oral medications to your prescriber
- Other semaglutide products or GLP-1 receptor agonists (e.g., liraglutide, dulaglutide, exenatide): should not be combined with Wegovy or Ozempic
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Personal or family history of medullary thyroid cancer (MTC) or MEN 2 — semaglutide is contraindicated; do not use
- Prior serious allergic reaction to semaglutide — do not use again
- History of pancreatitis — Ozempic labeling advises considering a different diabetes medication
- Pregnancy — semaglutide may harm the developing baby; stop at least 2 months before trying to conceive because the drug stays in the body for several weeks after the last dose; for MASH, discuss risks and benefits with your doctor
- Breastfeeding — Wegovy tablets are not recommended while nursing because of an ingredient called SNAC that may accumulate in infants; discuss Wegovy injection with your doctor
- Children under 12 — only Wegovy injection is approved for weight management in adolescents 12 and older; Ozempic and Wegovy tablets are not approved in children
- Diabetic eye disease (retinopathy) — patients with this history using Ozempic should be monitored closely for worsening
- Severe gastroparesis (very delayed stomach emptying) — Ozempic is not recommended in these patients
- Type 1 diabetes — Ozempic is not indicated for type 1 diabetes
🚑If you take too much▾
Taking too much semaglutide can cause severe nausea, severe vomiting, and dangerously low blood sugar. Because semaglutide stays in the body for about a week after the last dose, symptoms may need to be watched and treated for an extended period. If you think you or someone else has taken too much, call Poison Control at 1-800-222-1222 or seek emergency medical care right away.
📡Pharmacodynamics — effects in the body▾
Semaglutide lowers blood sugar by stimulating the pancreas to release more insulin when blood sugar is high and by reducing glucagon (the hormone that raises blood sugar) — both in a glucose-dependent way, meaning it does not over-stimulate insulin when blood sugar is already normal. It also reduces appetite and calorie intake, leading to weight loss with more fat lost than lean muscle. Additionally, semaglutide slows gastric emptying (how fast the stomach moves food along), which blunts blood sugar spikes after meals. Studies also show it can reduce liver fat content and markers of liver stiffness and scarring, though the full clinical meaning of these changes is still being confirmed.
🔬Pharmacokinetics — how your body processes it▾
After a subcutaneous (under-the-skin) injection, semaglutide is very well absorbed — about 89% reaches the bloodstream — and peak levels are reached within 1 to 3 days. The oral Wegovy tablet has much lower absorption (roughly 1–2%) because the drug must survive the digestive process; peak levels are reached about 1 hour after swallowing. Semaglutide binds tightly to a blood protein called albumin, which slows its clearance and gives it a half-life of approximately 1 week — meaning it stays active in the body for 5 to 7 weeks after the last dose. It is broken down primarily by enzymes in the body (proteolysis) and its breakdown products are eliminated through both urine and feces.
📦How to store it▾
• Do not store WEGOVY in the freezer or directly adjacent to the refrigerator cooling element. Do not freeze WEGOVY and do not use if it has been frozen. Store the WEGOVY prefilled single-dose pen or single-dose syringe in the refrigerator from 2°C to 8°C (36°F to 46°F).
📄 Written from Semaglutide’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
Supplements & herbs that interact with Semaglutide
256 supplements and herbal products have documented interactions with Semaglutide in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 2
- Moderate · 215
- Minor · 39
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrient depletion considerations
Semaglutide has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Semaglutide — the kind of thing our pharmacy team would talk through with you at the counter.
What's the difference between Ozempic and Wegovy — aren't they the same drug? ▾
I feel nauseous all the time since starting this. Is that normal, and will it go away? ▾
I keep seeing news about thyroid cancer risk. Should I be worried? ▾
Can I take my other medications at the same time as the Wegovy tablet? ▾
Is it safe to take this if I'm pregnant or trying to get pregnant? ▾
What signs would tell me something is seriously wrong and I need to call a doctor or go to the ER? ▾
Is Semaglutide available over the counter? ▾
When was Semaglutide first available? ▾
Who makes Semaglutide? ▾
💬 Answers drafted from Semaglutide’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Semaglutide comes
Semaglutide is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
Show 11 more strengths Show fewer strengths
Tablet
Show 1 more strength Show fewer strengths
📊 Semaglutide across the U.S. market
How Semaglutide appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (92) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Semaglutide is used
A general measure of how commonly Semaglutide is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Semaglutide is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Semaglutide prescribed? Of the 1,596 medications we measure, Semaglutide ranks #31 by Medicaid prescriptions — more than 98% of them.
Utilization by Semaglutide product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
0.25 MG, 0.5 MG Dose 3 ML semaglutide 0.68 MG/ML Pen Injector Most dispensed
Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2619152
3 ML semaglutide 2.68 MG/ML Pen Injector
Summed across the 1 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2599362
3 ML semaglutide 1.34 MG/ML Pen Injector
Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2398841
0.75 ML semaglutide 3.2 MG/ML Auto-Injector
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2554102
0.5 ML semaglutide 1 MG/ML Auto-Injector
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2553601
0.5 ML semaglutide 0.5 MG/ML Auto-Injector
Summed across the 1 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2553501
0.5 ML semaglutide 2 MG/ML Auto-Injector
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2553802
0.75 ML semaglutide 2.27 MG/ML Auto-Injector
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2553901
semaglutide 14 MG Oral Tablet
Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2200644
semaglutide 7 MG Oral Tablet
Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2200656
semaglutide 3 MG Oral Tablet
Summed across the 1 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2200652
Other Semaglutide products — combination packs and listings not yet matched to a specific clinical product (kept visible so every prescription is accounted for)
Summed across the 1 of 339 listed NDC products with Medicaid activity.
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Semaglutide, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 13 of 379 listed Semaglutide NDCs with Medicaid activity.
🔍 Compare Semaglutide products
A representative set of FDA-listed product records for Semaglutide — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 0.25 mg/0.5 mL | Subcutaneous | A-S Medication Solutions × 3 listings | NDA | View NDC → |
| 0.68 mg/mL | Subcutaneous | A-S Medication Solutions | NDA | View NDC → |
| 1.34 mg/mL | Subcutaneous | A-S Medication Solutions × 4 listings | NDA | View NDC → |
| 2.68 mg/mL | Subcutaneous | A-S Medication Solutions × 2 listings | NDA | View NDC → |
| 1.7 mg/0.75 mL | — | Catalent Indiana, LLC | DRUG FOR FURTHER PROCESSING | View NDC → |
| 2.4 mg/0.75 mL | — | Catalent Indiana, LLC | DRUG FOR FURTHER PROCESSING | View NDC → |
| 0.25 mg/0.5 mL | Subcutaneous | Novo Nordisk × 2 listings | NDA | View NDC → |
| 0.5 mg/0.5 mL | Subcutaneous | Novo Nordisk × 2 listings | NDA | View NDC → |
| 0.68 mg/mL | Subcutaneous | Novo Nordisk × 2 listings | NDA | View NDC → |
| 1 mg/0.5 mL | Subcutaneous | Novo Nordisk × 2 listings | NDA | View NDC → |
| 1.34 mg/mL | Subcutaneous | Novo Nordisk × 5 listings | NDA | View NDC → |
| 1.7 mg/0.75 mL | Subcutaneous | Novo Nordisk × 2 listings | NDA | View NDC → |
| 2.4 mg/0.75 mL | Subcutaneous | Novo Nordisk × 2 listings | NDA | View NDC → |
| 2.68 mg/mL | Subcutaneous | Novo Nordisk × 2 listings | NDA | View NDC → |
| 0.25 mg/0.5 mL | — | Novo Nordisk A/S | DRUG FOR FURTHER PROCESSING | View NDC → |
| 0.5 mg/0.5 mL | — | Novo Nordisk A/S | DRUG FOR FURTHER PROCESSING | View NDC → |
| 0.68 mg/mL | — | Novo Nordisk A/S | DRUG FOR FURTHER PROCESSING | View NDC → |
| 1 mg/0.5 mL | — | Novo Nordisk A/S | DRUG FOR FURTHER PROCESSING | View NDC → |
| 1.7 mg/0.75 mL | — | Novo Nordisk A/S | DRUG FOR FURTHER PROCESSING | View NDC → |
| 2.4 mg/0.75 mL | — | Novo Nordisk A/S | DRUG FOR FURTHER PROCESSING | View NDC → |
| 2.68 mg/mL | — | Novo Nordisk A/S | DRUG FOR FURTHER PROCESSING | View NDC → |
| 0.25 mg/0.5 mL | Subcutaneous | Novo Nordisk Pharmaceutical Industries, LP × 4 listings | NDA | View NDC → |
| 0.5 mg/0.5 mL | Subcutaneous | Novo Nordisk Pharmaceutical Industries, LP × 4 listings | NDA | View NDC → |
| 0.5 mg/mL | Subcutaneous | Novo Nordisk Pharmaceutical Industries, LP × 2 listings | NDA | View label ↗ |
| 0.68 mg/mL | Subcutaneous | Novo Nordisk Pharmaceutical Industries, LP × 2 listings | NDA | View NDC → |
| 1 mg/0.5 mL | Subcutaneous | Novo Nordisk Pharmaceutical Industries, LP × 4 listings | NDA | View NDC → |
| 1 mg/mL | Subcutaneous | Novo Nordisk Pharmaceutical Industries, LP × 2 listings | NDA | View label ↗ |
| 1.34 mg/mL | Subcutaneous | Novo Nordisk Pharmaceutical Industries, LP × 2 listings | NDA | View NDC → |
| 1.7 mg/0.75 mL | Subcutaneous | Novo Nordisk Pharmaceutical Industries, LP × 3 listings | NDA | View NDC → |
| 2 mg/mL | Subcutaneous | Novo Nordisk Pharmaceutical Industries, LP × 2 listings | NDA | View label ↗ |
| 2.27 mg/mL | Subcutaneous | Novo Nordisk Pharmaceutical Industries, LP × 2 listings | NDA | View label ↗ |
| 2.4 mg/0.75 mL | Subcutaneous | Novo Nordisk Pharmaceutical Industries, LP × 3 listings | NDA | View NDC → |
| 2.68 mg/mL | Subcutaneous | Novo Nordisk Pharmaceutical Industries, LP × 2 listings | NDA | View NDC → |
| 3.2 mg/mL | Subcutaneous | Novo Nordisk Pharmaceutical Industries, LP × 4 listings | NDA | View label ↗ |
| 7.2 mg/0.75 mL | Subcutaneous | Novo Nordisk Pharmaceutical Industries, LP × 3 listings | NDA | View NDC → |
| 0.5 mg/0.5 mL | — | Novo Nordisk Production Belgium SA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 0.5 mg/mL | — | Novo Nordisk Production Belgium SA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 1 mg/0.5 mL | — | Novo Nordisk Production Belgium SA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 1 mg/mL | — | Novo Nordisk Production Belgium SA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 1.7 mg/0.75 mL | — | Novo Nordisk Production Belgium SA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 2 mg/0.5 mL | — | Novo Nordisk Production Belgium SA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 2 mg/mL | — | Novo Nordisk Production Belgium SA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 2.27 mg/0.75 mL | — | Novo Nordisk Production Belgium SA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 2.4 mg/0.75 mL | — | Novo Nordisk Production Belgium SA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 3.2 mg/0.75 mL | — | Novo Nordisk Production Belgium SA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 0.25 mg/0.5 mL | — | Patheon Manufacturing Services LLC | DRUG FOR FURTHER PROCESSING | View NDC → |
| 0.5 mg/0.5 mL | — | Patheon Manufacturing Services LLC | DRUG FOR FURTHER PROCESSING | View NDC → |
| 1 mg/0.5 mL | — | Patheon Manufacturing Services LLC | DRUG FOR FURTHER PROCESSING | View NDC → |
| 1.7 mg/0.75 mL | — | Patheon Manufacturing Services LLC | DRUG FOR FURTHER PROCESSING | View NDC → |
| 2.4 mg/0.75 mL | — | Patheon Manufacturing Services LLC | DRUG FOR FURTHER PROCESSING | View NDC → |
| 💊Tablet | ||||
| 3 mg | — | Novo Nordisk A/S | DRUG FOR FURTHER PROCESSING | View NDC → |
| 7 mg | — | Novo Nordisk A/S | DRUG FOR FURTHER PROCESSING | View NDC → |
| 14 mg | — | Novo Nordisk A/S | DRUG FOR FURTHER PROCESSING | View NDC → |
| 1.5 mg | Oral | Novo Nordisk Pharmaceutical Industries, LP × 3 listings | NDA | View NDC → |
| 4 mg | Oral | Novo Nordisk Pharmaceutical Industries, LP × 3 listings | NDA | View NDC → |
| 9 mg | Oral | Novo Nordisk Pharmaceutical Industries, LP × 3 listings | NDA | View NDC → |
| 25 mg | Oral | Novo Nordisk Pharmaceutical Industries, LP × 3 listings | NDA | View NDC → |
| 💊Bulk drug substance | ||||
| 1 kg/kg | — | Apicore Pharmaceuticals private Limited | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Aurisco Pharmaceutical Co.,Ltd × 3 listings | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 5 g/5 g | — | Aurisco Pharmaceutical Co.,Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 10 g/10 g | — | Aurisco Pharmaceutical Co.,Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 20 g/20 g | — | Aurisco Pharmaceutical Co.,Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 50 g/50 g | — | Aurisco Pharmaceutical Co.,Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 kg/kg | — | Aurisco Pharmaceutical Co.,Ltd × 2 listings | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Bachem AG | BULK INGREDIENT | View NDC → |
| 100 g/100 g | — | Bills Biotech Pvt. Ltd. × 2 listings | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Biocon Limited | BULK INGREDIENT | View NDC → |
| 1 mg/mg | — | Chatnaa Life Sciences LLC | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Chengdu Brilliant Biopharmaceutical Co., Ltd. | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Chengdu Shengnuo Biopharm Co. Ltd. × 3 listings | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 kg/kg | — | Chengdu Shengnuo Biopharm Co. Ltd. | BULK INGREDIENT | View NDC → |
| 1000 g/1000 g | — | Chengdu Shengnuo Biopharm Co. Ltd. | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 g/g | — | Chinese Peptide Company | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Chongqing Sintaho Pharmaceutical Co., Ltd. | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Chunghwa Chemical Synthesis & Biotech Co., Ltd. | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Darmerica, Llc | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Dr. Reddys Laboratories Limited | BULK INGREDIENT | View NDC → |
| 1 g/g | — | El-Peptido (Shanghai) Biopharmaceutical Co., Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 g/g | — | Fujian Genohope Biotech Ltd. × 5 listings | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Guangdong HEC Bio&Pharm Co., Ltd. | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 kg/kg | — | Hainan Poly Pharm. Co., Ltd. | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 g/g | — | Hangzhou Jodomi Biotech Co.,Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 kg/kg | — | Hetero Drugs Limited | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Hubei JXBio Pharmaceutical Co.,Ltd | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Hubei JXBio Pharmaceutical Co.,Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 g/g | — | Hybio Pharmaceutical Co., Ltd | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Hybio Pharmaceutical Co., Ltd. | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Hybio Pharmaceutical Co. Ltd × 9 listings | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 g/g | — | Hybio Pharmaceutical Co. Ltd × 5 listings | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Medisca Inc. | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | MSN Life Sciences Private Limited | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Nanjing Hanxin Pharmaceutical Technology Co., Ltd. | BULK INGREDIENT | View NDC → |
| 1 mg/mg | — | Nomida Llc | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Novo Nordisk A/S × 2 listings | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Pharma Source Direct, Inc. | BULK INGREDIENT | View NDC → |
| 1 g/g | — | PolyPeptide SA | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Qingdao Biopeptek Co., Ltd. | BULK INGREDIENT | View NDC → |
| 100 g/100 g | — | SCH Global Services Private Limited | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Shanghai Ambiopharm, Inc | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Shenzhen Alvantis Pharma Co., Ltd. | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 g/g | — | Shilpa Pharma Lifesciences Limited | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 g/g | — | Sichuan Jisheng Biopharmaceutical Co Ltd | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Sinopep-Allsino Biopharmaceutical Co., Ltd. × 2 listings | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Sinopep-Allsino Biopharmaceutical Co., Ltd. × 2 listings | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 g/g | — | Supriya Lifescience Limited | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Suzhou Lixin Pharmaceutical Co., Ltd. | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 g/g | — | Thaeta Scientific LLC | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 g/g | — | Virtu Pharmako (Zhejiang) Co., Ltd. × 6 listings | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Zhejiang Kingland Pharmaceutical Company Limited × 5 listings | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Zhejiang Peptites Biotech Co., Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 g/g | — | Zhejiang Tasln Biopharma Co., Ltd. | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 g/g | — | Zhejiang Tasln Biopharma Co., Ltd. | BULK INGREDIENT | View NDC → |
| 100 g/100 g | — | Zhuhai Readline Biotech Co., Ltd. | BULK INGREDIENT | View NDC → |
Showing 199 of 199 products — FDA National Drug Code Directory. See every product, package size and price: browse all 199 Semaglutide NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Semaglutide — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Semaglutide in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Semaglutide went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 1991302 3 dose forms · 17 strengths
-
Dose form (SCDF) Auto-Injector RxCUI 2553500In current FDA listingsClinical drug / strength (SCD) 0.5 ML semaglutide 0.5 MG/MLRxCUI 25535010.5 ML semaglutide 1 MG/MLRxCUI 25536010.5 ML semaglutide 2 MG/MLRxCUI 25538020.75 ML semaglutide 2.27 MG/MLRxCUI 25539010.75 ML semaglutide 3.2 MG/MLRxCUI 25541020.75 ML semaglutide 9.6 MG/MLRxCUI 2739768 -
Dose form (SCDF) Oral Tablet RxCUI 2200643In current FDA listings -
Dose form (SCDF) Pen Injector RxCUI 1991305In current FDA listingsClinical drug / strength (SCD) 0.25 MG, 0.5 MG Dose 3 ML semaglutide 0.68 MG/MLRxCUI 26191523 ML semaglutide 1.34 MG/MLRxCUI 23988413 ML semaglutide 2.68 MG/MLRxCUI 25993623 ML semaglutide 3.2 MG/MLRxCUI 2745801
Look up RxCUI 1991302 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Semaglutide is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
…and 16 more on the FDA NDC directory.
RxNorm drug class
Semaglutide belongs to the GLP-1 Receptor Agonist class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 6 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Novo Nordisk is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.